Global Deep Vein Thrombosis Market

Report ID : 1070 | Published : 2022-08-16 | Pages: 140 | Format: PDF/EXCEL

Deep vein thrombosis (DVT) is a serious condition that occurs when clots forms in the deep veins of the body. The most dangerous complication of deep vein thrombosis is pulmonary embolism (PE), which can either be asymptomatic or symptomatic. Surgery and pregnancy are the major risk factors associated with deep vein thrombosis. Pregnancy increase hormone level and slower blood flow lead to expansion of uterus and restrict blood flowing back from lower extremities responsible for deep vein thrombosis. Diagnosis of deep vein thrombosis can be made with blood tests such as D-dimer test and imaging tests such as Doppler ultrasound (Duplex), contrast venogram, magnetic resonance imaging (MRI), and computer tomography (CT). There are four types of treatments for deep vein thrombosis include anticoagulant, thrombolytic therapy, IVC filters (Vein Filters), and Stents. Anticoagulant such as unfractionated heparin, low molecular weight heparin (enoxaparin/ Lovenox, dalteparin/Fragmin, or tinzaparin/Innohep, fondaparinux/Arixtra or desirudin/Iprivask), warfarin (Coumadin and Jantoven) are the primary treatment deep vein thrombosis. Thrombolytic therapy such as tissue plasminogen activator agents (tPA) can help to dissolve the blood clot. IVC filters (Vein Filters), also known as “Greenfield filters,” is an umbrella-shaped device that is placed into the large vein, which traps blood clots and prevents deep vein thrombosis and pulmonary embolism. Stents are metal meshwork tubes that are placed into a vein to keep them open.

Almost one-half million patients are hospitalized for venous thromboembolism (consist of deep vein thrombosis and pulmonary embolism) each year in the United States. In Europe, there are 544,000 venous thromboembolism related death every year. Venous thromboembolism can cause a significant global economic burden. Various diagnostic tests and treatment, prolonged hospital stay, and follow-up care can be extremely costly; for instance estimated medical cost for venous thromboembolism in the U.S is $5-10 billion per year. In U.K venous thromboembolism related cost is 750 million per year. In Australia, venous thromboembolism related costs are estimated at 1.72 billion a year. In June 2017, U.S. FDA (Food and Drug Administration) approved betrixaban (Portola) for the adult with venous thromboembolism (VTE). Pentasaccharides such XARELTO are novel anticoagulants may be preferred over standard therapy due to few drug interactions and no need for frequent monitoring or re-dosing.
Prominent key players operating deep vein thrombosis (DVT) market are Sandoz Inc. Teva Pharmaceuticals USA, Inc. Sanofi-Aventis U.S. LLC, Pfizer Inc. Baxter International Inc., West-Ward Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc. and others.

 

 

  • Sandoz Inc
  • Teva Pharmaceuticals USA, Inc.
  • Sanofi-Aventis U.S. LLC
  • Pfizer Inc
  • Baxter International Inc
  • West-Ward Pharmaceuticals
  • Boehringer Ingelheim Pharmaceuticals, Inc
  • Other Prominent Player

Global Deep Vein Thrombosis Market Outlook (Revenue, US$ Mn, 2019 – 2030) By Region

  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • North America
    • U.S.
    • Canada
  • Asia Pacific
    • India
    • China
    • Japan
    • South Korea
    • Australia & New Zealand
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Our Clients

Media Citations

Growth opportunities and latent adjacency in Pharmaceuticals

Select Licence Type
$3786
$10000
Get a Custom Report
Contact us with a specific research request.

Kindly share us with a topic or product segment or objectives to meet your strategy goals

Review Request

We’ll review your request & send a personalized quote for cost and time needed

Final Delivery

Sit back while our team work on your research. We will send bi-monthly updates and discuss our finding on a conference call upon final delivery..